S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
Log in
ASX:EMV

EMvision Medical Devices Limited (EMV.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.92
MA: A$0.91▼
A$0.92
52-Week Range N/A
Volume192,157 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
EMvision Medical Devices Limited engages in the research, development, and commercialization of imaging and diagnostic technology for the purpose of commercializing portable medical device for stroke diagnosis and monitoring, and other medical imaging needs. The company has a strategic collaboration with Keysight Technologies Malaysia Sdn Bhd to develop a personalized vector network analysis solution for medical imaging in the healthcare sector. EMvision Medical Devices Limited was founded in 2017 and is based in Rozelle, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Current SymbolASX:EMV
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.emvision.com.au
Phone61 2 8667 5337
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio11.30
Quick Ratio11.21

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.60 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow8.47
Book ValueA$0.09 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive EMV News and Ratings via Email

Sign-up to receive the latest news and ratings for EMV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











EMvision Medical Devices Limited (EMV.AX) (ASX:EMV) Frequently Asked Questions

How were EMvision Medical Devices Limited (EMV.AX)'s earnings last quarter?

EMvision Medical Devices Limited (EMV.AX) (ASX:EMV) posted its quarterly earnings data on Tuesday, February, 26th. The company reported ($4.47) EPS for the quarter.
View EMvision Medical Devices Limited (EMV.AX)'s earnings history.

Who are some of EMvision Medical Devices Limited (EMV.AX)'s key competitors?

Some companies that are related to EMvision Medical Devices Limited (EMV.AX) include Adherium Limited (ADR.AX) (ADR), ADM Tronics Unlimited (ADMT), ADM Tronics Unlimited (ADMT), ALR Technologies (ALRT), Analytica Limited (ALT.AX) (ALT), AnteoTech Limited (ADO.AX) (ADO), Atomo Diagnostics Limited (AT1.AX) (AT1), Avita Medical (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), Cochlear (CHEOY), Cochlear (CHEOF), Cochlear Limited (COH.AX) (COH), Cyclopharm Limited (CYC.AX) (CYC) and Fisher & Paykel Healthcare Co. Limited (FPH.AX) (FPH).
View all competitors.

Who are EMvision Medical Devices Limited (EMV.AX)'s key executives?

EMvision Medical Devices Limited (EMV.AX)'s management team includes the following people:
  • Dr. Ronald Peter Weinberger, CEO, MD & Director
  • Mr. Scott Kirkland, Exec. Director
  • Ms. Emma Waldon, CFO & Company Sec. (Age 44)
  • Dr. Konstanty Bialkowski, Head of Technology Devel.
  • Ms. Ruth Cremin, Head of Quality & Regulatory Affairs

What is EMvision Medical Devices Limited (EMV.AX)'s stock symbol?

EMvision Medical Devices Limited (EMV.AX) trades on the ASX under the ticker symbol "EMV."

How big of a company is EMvision Medical Devices Limited (EMV.AX)?

EMvision Medical Devices Limited (EMV.AX) has a market capitalization of $0.00 and generates $1.60 million in revenue each year.

What is EMvision Medical Devices Limited (EMV.AX)'s official website?

The official website for EMvision Medical Devices Limited (EMV.AX) is www.emvision.com.au.

How can I contact EMvision Medical Devices Limited (EMV.AX)?

The company can be reached via phone at 61 2 8667 5337.

This page was last updated on 10/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.